1. |
赵玉沛. 胰腺癌诊断与治疗的现状与未来. 中华肝胆外科杂志, 2009, 15(5): 321-323.
|
2. |
中国临床肿瘤学会胰腺癌专家委员会. 胰腺癌综合诊治中国专家共识(2014年版). 临床肿瘤学杂志, 2014, 19(4): 358-370.
|
3. |
Okabayashi T, Shima Y, Iwata J, et al. S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas. World J Surg, 2014, 38(11): 2986-2993.
|
4. |
Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg, 2007, 246(2): 173-180.
|
5. |
Kamisawa T, Wood LD, Itoi T, et al. Pancreatic cancer. Lancet, 2016, 388(10039): 73-85.
|
6. |
Jamieson NB, Denley SM, Logue J, et al. A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. Ann Surg Oncol, 2011, 18(8): 2318-2328.
|
7. |
Antonioli L, Blandizzi C, Pacher P, et al. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer, 2013, 13(12): 842-857.
|
8. |
Li N, Tian GW, Wang Y, et al. Prognostic role of the pretreatment C-reactive protein/albumin ratio in solid cancers: a meta-analysis. Sci Rep, 2017, 7: 41298. doi: 10.1038/srep41298.
|
9. |
Ventriglia J, Petrillo A, Huerta Alváro M, et al. Neutrophil to lymphocyte ratio as a predictor of poor prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine: a propensity score analysis. Gastroenterol Res Pract, 2018, 2018: 2373868. doi: 10.1155/2018/2373868.
|
10. |
Maruyama H, Hirano S, Kakiya Y, et al. Tu1440 – Preoperative C-reactive protein/albumin ratio predicts cancerization and recurrence in patients with resectable intraductal papillary mucinous neoplasms. Gastroenterology, 2019, 156(6): S-1040. doi: 10.1016/S0016-5085(19)39553-8.
|
11. |
Yılmaz EM, Kandemir A. Significance of red blood cell distribution width and C-reactive protein/albumin levels in predicting prognosis of acute pancreatitis. Ulus Travma Acil Cerrahi Derg, 2018, 24(6): 528-531.
|
12. |
Fan Y, Xiang S, Dai Z, et al. Prognostic significance of C-reactive protein to albumin ratio in colorectal cancer patients: a meta-analysis. Int J Colorectal Dis, 2019, 34(6): 1105-1111.
|
13. |
Wei XL, Wang FH, Zhang DS, et al. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. BMC Cancer, 2015, 15: 350. doi: 10.1186/s12885-015-1379-6.
|
14. |
Deng TB, Zhang J, Zhou YZ, et al. The prognostic value of C-reactive protein to albumin ratio in patients with lung cancer. Medicine (Baltimore), 2018, 97(50): e13505. doi: 10.1097/MD.0000000000013505.
|
15. |
Zhou W, Zhang GL. C-reactive protein to albumin ratio predicts the outcome in renal cell carcinoma: a meta-analysis. PLoS One, 2019, 14(10): e0224266. doi: 10.1371/journal.pone.0224266.
|
16. |
Cui X, Jia Z, Chen D, et al. The prognostic value of the C-reactive protein to albumin ratio in cancer: an updated meta-analysis. Medicine (Baltimore), 2020, 99(14): e19165. doi: 10.1097/MD.0000000000019165.
|
17. |
Park HC, Kim MY, Kim CH. C-reactive protein/albumin ratio as prognostic score in oral squamous cell carcinoma. J Korean Assoc Oral Maxillofac Surg, 2016, 42(5): 243-250.
|
18. |
Piciucchi M, Stigliano S, Archibugi L, et al. The neutrophil/lymphocyte ratio at diagnosis is significantly associated with survival in metastatic pancreatic cancer patients. Int J Mol Sci, 2017, 18(4): 730. doi: 10.3390/ijms18040730.
|
19. |
Lee JM, Lee HS, Hyun JJ, et al. Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib. World J Gastrointest Oncol, 2016, 8(7): 555-562.
|
20. |
Wu M, Guo J, Guo L, et al. The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer. Tumour Biol, 2016, 37(9): 12525-12533.
|
21. |
Haruki K, Shiba H, Shirai Y, et al. The C-reactive protein to albumin ratio predicts long-term outcomes in patients with pancreatic cancer after pancreatic resection. World J Surg, 2016, 40(9): 2254-2260.
|
22. |
Hang J, Xue P, Yang H, et al. Pretreatment C-reactive protein to albumin ratio for predicting overall survival in advanced pancreatic cancer patients. Sci Rep, 2017, 7(1): 2993. doi: 10.1038/s41598-017-03153-6.
|
23. |
Liu Z, Jin K, Guo M, et al. Prognostic value of the CRP/Alb ratio, a novel inflammation-based score in pancreatic cancer. Ann Surg Oncol, 2017, 24(2): 561-568.
|
24. |
Ikeguchi M, Hanaki T, Endo K, et al. C-reactive protein/albumin ratio and prognostic nutritional index are strong prognostic indicators of survival in resected pancreatic ductal adenocarcinoma. J Pancreat Cancer, 2017, 3(1): 31-36.
|
25. |
Fujiwara Y, Haruki K, Shiba H, et al. C-reactive protein-based prognostic measures are superior at predicting survival compared with peripheral blood cell count-based ones in patients after curative resection for pancreatic cancer. Anticancer Res, 2018, 38(11): 6491-6499.
|
26. |
Arima K, Yamashita YI, Hashimoto D, et al. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Am J Surg, 2018, 216(1): 111-115.
|
27. |
罗宝洋, 杨勇, 段云飞, 等. 术前C反应蛋白和清蛋白比值对可切除胰腺癌患者预后的影响. 中华外科杂志, 2018, 56(9): 712-717.
|
28. |
Kim HJ, Lee SY, Kim DS, et al. Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy. Korean J Intern Med, 2020, 35(1): 171-184.
|
29. |
Ikuta S, Aihara T, Yamanaka N. Preoperative C-reactive protein to albumin ratio is a predictor of survival after pancreatic resection for pancreatic ductal adenocarcinoma. Asia Pac J Clin Oncol, 2019, 15(5): e109-e114. doi: 10.1111/ajco.13123.
|
30. |
Vujic J, Marsoner K, Wienerroither V, et al. The predictive value of the CRP-to-albumin ratio for patients with pancreatic cancer after curative resection: a retrospective single center study. In Vivo, 2019, 33(6): 2071-2078.
|
31. |
Fan Z, Fan K, Gong Y, et al. The CRP/albumin ratio predicts survival and monitors chemotherapeutic effectiveness in patients with advanced pancreatic cancer. Cancer Manag Res, 2019, 11: 8781-8788.
|
32. |
Murakawa M, Yamamoto N, Kamioka Y, et al. Clinical implication of pre-operative C-reactive protein-albumin ratio as a prognostic factor of patients with pancreatic ductal adenocarcinoma: a single-institutional retrospective study. In Vivo, 2020, 34(1): 347-353.
|
33. |
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 2009, 339: b2535. doi: 10.1136/bmj.b2535.
|
34. |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
|
35. |
Alifano M, Mansuet-Lupo A, Lococo F, et al. Systemic inflammation, nutritional status and tumor immune microenvironment determine outcome of resected non-small cell lung cancer. PLoS One, 2014, 9(9): e106914. doi:10.1371/journal.pone.0106914.
|
36. |
Zhang J, Zhang HY, Li J, et al. The elevated NLR, PLR and PLT may predict the prognosis of patients with colorectal cancer: a systematic review and meta-analysis. Oncotarget, 2017, 8(40): 68837-68846.
|
37. |
Zhou Y, Wei Q, Fan J, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysis containing8 252 patients. Clin Chim Acta, 2018, 479: 181-189.
|
38. |
Chen H, Hu N, Chang P, et al. Modified Glasgow prognostic score might be a prognostic factor for hepatocellular carcinoma: a meta-analysis. Panminerva Med, 2017, 59(4): 302-307.
|
39. |
Zhou Y, Cheng S, Fathy AH, et al. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Onco Targets Ther, 2018, 11: 1899-1908.
|
40. |
Dequanter D, Lothaire P. Serum albumin concentration and surgical site identify surgical risk for major post-operative complications in advanced head and neck patients. B-ENT, 2011, 7(3): 181-183.
|
41. |
Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J, 2010, 9: 69. doi: 10.1186/1475-2891-9-69.
|
42. |
Stevens L, Pathak S, Nunes QM, et al. Prognostic significance of pre-operative C-reactive protein and the neutrophil-lymphocyte ratio in resectable pancreatic cancer: a systematic review. HPB (Oxford), 2015, 17(4): 285-291.
|
43. |
Qu G, Wang D, Xu W, et al. The systemic inflammation-based prognostic score predicts postoperative complications in patients undergoing pancreaticoduodenectomy. Int J Gen Med, 2021, 14: 787-795.
|
44. |
Serafini S, Friziero A, Sperti C, et al. The ratio of C-reactive protein to albumin is an independent predictor of malignant intraductal papillary mucinous neoplasms of the pancreas. J Clin Med, 2021, 10(10): 2058. doi: 10.3390/jcm10102058.
|
45. |
Makiyama A, Nakazawa J, Otsuka T, et al. Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: based on the results of a multicenter retrospective study (the NAPOLEON study). Ann Oncol, 2019, 30: ix58. doi: org/10.1093/annonc/mdz422.044.
|
46. |
van Wijk L, de Klein GW, Kanters MA, et al. The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection. Eur J Med Res, 2020, 25(1): 46. doi: 10.1186/s40001-020-00444-z.
|
47. |
Zang Y, Fan Y, Gao Z. Pretreatment C-reactive protein/albumin ratio for predicting overall survival in pancreatic cancer: a meta-analysis. Medicine (Baltimore), 2020, 99(23): e20595. doi: 10.1097/MD.0000000000020595.
|
48. |
Wu J, Tan W, Chen L, et al. Clinicopathologic and prognostic significance of C-reactive protein/albumin ratio in patients with solidtumors: an updated systemic review and meta-analysis. Oncotarget, 2018, 9: 13934-13947.
|